在肝癌中,FBXW11通过ubiquitinatingYB1抑制瘤发生
Wuguang Liu1, Bin Xu1, Tong Wang1
1Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, The Second Hospital of Dalian Medical University, Dalian, 116027, China.
FBXW11通过向YB1进行降解来抑制肝细胞癌 (HCC),抑制Akt/mTOR通路. 这个FBXW11-YB1轴为HCC治疗提供了一个新的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- 肝细胞癌 (HCC) 是一个主要的全球健康问题,有效的治疗方法有限.
- 了解推动HCC进展的分子机制对于开发新型治疗策略至关重要.
研究的目的:
- 调查FBXW11在HCC发病过程中的作用.
- 阐明FBXW11调节YB1泛化的机制及其对HCC的影响.
- 探索FBXW11-YB1轴在HCC进展中的功能意义.
主要方法:
- 在临床HCC标本和细胞系中分析FBXW11和YB1表达.
- 功能增益和丧失研究,以评估FBXW11对HCC细胞增殖的影响.
- 共同免疫沉,质谱和无处可见度测试以确定蛋白质相互作用和无处可见度.
- 在体内异种移植模型评估瘤发生.
- 对与临床病理特征和生存率的相关性进行统计分析.
主要成果:
- 在HCC组织中,FBXW11表达显著下调,与晚期和低生存率相关.
- 过度表达FBXW11抑制了HCC细胞的增殖,而抑制则促进了它的增殖.
- FBXW11与YB1直接相互作用,促进其K48结合的多比基因化和蛋白质体降解.
- 在体内,FBXW11通过抑制YB1/Akt/mTOR信号通路来抑制瘤生长.
结论:
- FBXW11通过调解YB1的泛化和降解,作为HCC中的瘤抑制剂起作用,随后抑制了Akt/mTOR通路.
- FBXW11-YB1轴代表了肝癌发生的新型调节机制.
- FBXW11具有作为HCC的预后生物标志物和治疗点的潜力.
更多相关视频
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
08:50In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
相关概念视频
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
Inhibition of Cdk Activity
Induced Pluripotent Stem Cells
Somatic...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
TGF - β Signaling Pathway
